Enzon to Present at Credit Suisse First Boston Healthcare Conference.

BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that the company will participate in the Credit Suisse First Boston Healthcare Conference, which is being held November 17-19, 2004 in Phoenix, Arizona. Ken Zuerblis, Enzon's chief financial officer, will give a 25-minute presentation on Wednesday, November 17, 2004 at 3:30 p.m. MST or 5:30 p.m. EST.

The final schedule can be accessed at http://www.csfb.com/conferences/healthcare/client/agenda.shtml. A live webcast of the presentation may be accessed by visiting Enzon's website at www.enzon.com. For those unable to listen to the live broadcast, a replay of the webcast will also be available on the Company's website.

About Enzon

Enzon Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics to treat life-threatening diseases. The Company has developed or acquired a number of marketed products, including PEG-INTRON(R), marketed by Schering-Plough, and ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R), marketed in North America by Enzon's specialized sales force. Enzon's science-driven strategy includes an extensive drug development program that leverages the Company's macromolecular engineering technology platforms, including PEG modification and single-chain antibody (SCA(R)) technologies. Internal research and development efforts are complemented by strategic transactions that provide access to additional products and technologies. Enzon has several drug candidates in various stages of development, independently and with partners, including Marqibo(R) (formerly referred to as Onco TCS), for which a U.S. marketing application is currently being reviewed by the FDA for the treatment of relapsed aggressive non-Hodgkin's lymphoma. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.